Kiora reports 2024 net income $3.6M; two Phase 2 retinal trials approved; cash runway into 2027

KIORA PHARMACEUTICALS INC

Year-end cash, equivalents, and short-term investments $26.8M; expected runway into 2027.
Net income $3.6M in 2024 vs net loss $12.5M in 2023; Q4 2024 net loss $4.2M.
Received approval for KLARITY (Phase 2 KIO-104) and ABACUS-2 (Phase 2 KIO-301) studies.
Recognized $16M in collaboration revenue from Laboratoires Théa for KIO-301 in 2024.
Data readouts from both Phase 2 trials expected in 2026; first patient dosing in Q2 2025 for KLARITY.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.